Mobile Infirmary Medical Center

Summary

Mobile Infirmary Medical Center is a medical facility located in Mobile, Alabama. This center is recognized for care of Breast Cancer, Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Head and Neck Cancers and other specialties. Mobile Infirmary Medical Center is involved with conducting 89 clinical trials across 145 conditions. There are 8 research doctors associated with this hospital, such as Kannan Thanikachalam, Furhan Yunus, John R. Russell, and Jose N. Galeas.

Top PIs

Clinical Trials running at Mobile Infirmary Medical Center

Lung Cancer

Melanoma

Cutaneous Melanoma

Pancreatic Cancer

Breast Cancer

Ovarian Cancer

Breast cancer

Stroke

Fallopian Tube Cancer

Prostate Cancer

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Biobank Collection

for Cancer

This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.

Recruiting

1 award

N/A

10 criteria

Cemiplimab

for Non-Small Cell Lung Cancer

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.

Recruiting

1 award

Phase 2 & 3

19 criteria